Beyond Air Inc. $(XAIR)$ has announced its financial results for the fiscal fourth quarter and year ended March 31, 2025. The company reported a 220% increase in annual revenues, rising to $3.7 million from $1.2 million for the previous fiscal year ended March 31, 2024. Despite this significant growth in revenues, Beyond Air reported a net loss attributed to common stockholders of $46.6 million for the year ended March 31, 2025, compared to a net loss of $60.2 million for the previous fiscal year. Looking ahead, Beyond Air expects to report revenues of at least $1.7 million for the quarter ending June 30, 2025, and has introduced revenue guidance of $12 million to $16 million for the full fiscal year 2026. The company has also submitted a PMA supplement for its second-generation LungFit® PH to the FDA and continues to expand its international distribution partnerships, now covering markets representing over 2 billion lives. LungFit® PH is actively shipping to Europe, Australia, and the Middle East. Additionally, Robert Goodman, a seasoned healthcare executive, has been appointed to the company's Board of Directors.